AIM
ACTU

ABS Investment Management’s Actuate Therapeutics ACTU Stock Holding History

ABS Investment Management’s Portfolio ACTU Stock Details ACTU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$112K Buy
+73,186
New +$170K 0.07% 108

Other funds holding ACTU

BCM
BIOS Capital Management Fort Worth, Texas $41.7M AUM 34.92% 1-Year Est. Return
VC
Voss Capital Houston, Texas $2.15B AUM 33.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.87B AUM 24.49% 1-Year Est. Return
PVM
Palogic Value Management Dallas, Texas $304M AUM 15.15% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ADEF
ABS Direct Equity Fund Stamford, Connecticut $159M AUM 34.17% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
RCG
Rock Creek Group Washington, District of Columbia $994M AUM 11.29% 1-Year Est. Return

ABS Investment Management's ACTU Position: Q2 2026 in Review

ABS Investment Management opened a new position in Actuate Therapeutics (ACTU) in Q2 2026: 73,186 shares worth $112K. The stake represents 0.07% of the portfolio and ranks #108 among its holdings.

62 funds tracked by Wall St. Rank hold ACTU as of Q2 2026.

  • ABS Investment Management held 73,186 shares of Actuate Therapeutics worth $112K as of Q2 2026.
  • Actuate Therapeutics was a new ABS Investment Management position in Q2 2026.
  • Actuate Therapeutics made up 0.07% of ABS Investment Management's portfolio in Q2 2026, its #108 holding.
  • 62 funds tracked by Wall St. Rank held Actuate Therapeutics as of Q2 2026.

Based on ABS Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.